Robert B Jenkins

发表

HER2 testing in patients with breast cancer: poor correlation between weak positivity by immunohistochemistry and gene amplification by fluorescence in situ hybridization.

James N Ingle, Edith A Perez, E. Perez, 2002, Mayo Clinic proceedings.

Transcriptome-Wide Association Study Identifies New Candidate Susceptibility Genes for Glioma.

Karl-Heinz Jöckel, Jill S Barnholtz-Sloan, Jeanette E Eckel-Passow, 2019, Cancer research.

Nuclear MYC protein overexpression is an early alteration in human prostate carcinogenesis

Jun Luo, Tsuyoshi Iwata, Toby C. Cornish, 2008, Modern Pathology.

C-MYC alterations and association with patient outcome in early-stage HER2-positive breast cancer from the north central cancer treatment group N9831 adjuvant trastuzumab trial.

Peter A Kaufman, Lyndsay N Harris, James N Ingle, 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Concordance between local and central laboratory HER2 testing in the breast intergroup trial N9831.

Peter A Kaufman, James N Ingle, Edith A Perez, 2002, Journal of the National Cancer Institute.

Associations of high-grade glioma with glioma risk alleles and histories of allergy and smoking.

Faith Davis, Yuanyuan Xiao, Brooke L Fridley, 2011, American journal of epidemiology.

ERBB2, TBX2, RPS6KB1, and MYC alterations in breast tissues of BRCA1 and BRCA2 mutation carriers

Daniel J Schaid, Fergus Couch, Jeffrey M Slezak, 2004, Genes, chromosomes & cancer.

A germline variant in the TP53 polyadenylation signal confers cancer susceptibility

Kari Stefansson, Brian T Helfand, Torben Hansen, 2011, Nature Genetics.

TBX2 is preferentially amplified in BRCA1- and BRCA2-related breast tumors.

Fergus J Couch, Lynn Hartmann, Thomas A Sellers, 2002, Cancer research.

Pathologic characteristics of breast parenchyma in patients with hereditary breast carcinoma, including BRCA1 and BRCA2 mutation carriers

Daniel J Schaid, Jeffrey L Myers, Jeffrey M Slezak, 2003, Cancer.

Genomic analysis reveals that immune function genes are strongly linked to clinical outcome in the North Central Cancer Treatment Group n9831 Adjuvant Trastuzumab Trial.

Krishna R. Kalari, Jeanette E Eckel-Passow, Krishna R Kalari, 2015, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Human Epidermal Growth Factor Receptor 2 Testing in Breast Cancer: American Society of Clinical Oncology/College of American Pathologists Clinical Practice Guideline Focused Update.

John M S Bartlett, Patrick Fitzgibbons, Lisa M McShane, 2018, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

A chromosomal region 7p11.2 transcript map: its development and application to the study of EGFR amplicons in glioblastoma.

Soyeon Park, Robert B Jenkins, C David James, 2002, Neuro-oncology.

Trastuzumab plus adjuvant chemotherapy for operable HER2-positive breast cancer.

Greg Yothers, Peter A Kaufman, Norman Wolmark, 2005, The New England journal of medicine.

Recommendations for human epidermal growth factor receptor 2 testing in breast cancer: American Society of Clinical Oncology/College of American Pathologists clinical practice guideline update.

John M S Bartlett, Patrick Fitzgibbons, Mitch Dowsett, 2014, Archives of pathology & laboratory medicine.

Meta-analysis of 8q24 for seven cancers reveals a locus between NOV and ENPP2 associated with cancer development

Steven Gallinger, David V Conti, Honglin Song, 2011, BMC Medical Genetics.

Genome-wide association study of glioma subtypes identifies specific differences in genetic susceptibility to glioblastoma and non-glioblastoma tumors

Hugues Sicotte, Jill S Barnholtz-Sloan, Jeanette E Eckel-Passow, 2017, Nature Genetics.

The prognostic impact of histology and 1p/19q status in anaplastic oligodendroglial tumors

Caterina Giannini, Wei Zhang, Kenneth Hess, 2005, Cancer.

Immunohistochemical Detection of EGFRvIII in High Malignancy Grade Astrocytomas and Evaluation of Prognostic Significance

Caterina Giannini, Alfred Furth, Karla Ballman, 2004, Journal of neuropathology and experimental neurology.

Combined value of validated clinical and genomic risk stratification tools for predicting prostate cancer mortality in a high-risk prostatectomy cohort.

Anamaria Crisan, Elai Davicioni, Matthew R Cooperberg, 2015, European urology.

Genetic heterogeneity in HER2 testing in breast cancer: panel summary and guidelines.

Raymond R Tubbs, Patrick L Fitzgibbons, K. Bloom, 2009, Archives of pathology & laboratory medicine.

Phase I/II trial of erlotinib and temozolomide with radiation therapy in the treatment of newly diagnosed glioblastoma multiforme: North Central Cancer Treatment Group Study N0177.

Caterina Giannini, Jan C Buckner, Paul D Brown, 2008, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Recommendations for human epidermal growth factor receptor 2 testing in breast cancer: American Society of Clinical Oncology/College of American Pathologists clinical practice guideline update.

John M S Bartlett, Patrick Fitzgibbons, Mitch Dowsett, 2013, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Fusion of HMGA1 to the LPP/TPRG1 intergenic region in a lipoma identified by mapping paraffin-embedded tissues.

R. Jenkins, F. Medeiros, André M. Oliveira, 2010, Cancer genetics and cytogenetics.

Benefit from procarbazine, lomustine, and vincristine in oligodendroglial tumors is associated with mutation of IDH.

Caterina Giannini, Walter J Curran, Jan C Buckner, 2014, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Human Epidermal Growth Factor Receptor 2 Testing in Breast Cancer: American Society of Clinical Oncology/College of American Pathologists Clinical Practice Guideline Focused Update.

John M S Bartlett, Patrick Fitzgibbons, Lisa M McShane, 2018, Archives of pathology & laboratory medicine.

HER2 testing by local, central, and reference laboratories in specimens from the North Central Cancer Treatment Group N9831 intergroup adjuvant trial.

Peter A Kaufman, James N Ingle, Edith A Perez, 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.